News
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.
Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...
The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
1d
HealthDay on MSNCDC Now Recommends RSV Vaccine for Some Adults Aged 50 Years and OlderThe RSV vaccination eligibility age has been lowered from 60 years to 50 years according to an update on the CDC website.
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.
Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results